136. Argoff CE, Alford DP, Fudin J, et al. Rational urine drug monitoring in patients receiving opioids for chronic pain: consensus recommendations. Pain Med. 2018;19(1):97- 117. 137. Busse JW, Craigie S, Juurlink DN, et al. Guideline for opioid therapy and chronic noncancer pain. Can Med Assoc J. 2017;189(18):E659. 138. U.S. Department of Justice, National Drug Intelligence Center. National drug threat assessment summary 2014: Controlled prescription drugs. https:// info. publicintelligence.net/DEA-DrugThreats-2014.pdf. Published November 2014. Accessed 3-23-18. 139. Dowell D. 2019 CDC opioid guideline clarification letter to ASCO, ASH, NCCN. asco.org. www.asco.org/sites/new- www.asco.org/files/content-files/advocacy-and-policy/ documents/2019-CDC-Opioid-Guideline-Clarification- Letter-to-ASCO-ASH-NCCN.pdf Published February 28, 2019. Accessed April 30, 2021. 140. Federation of State Medical Boards (FSMB). Guidelines for the chronic use of opioid analgesics. https://www.fsmb. org/opioids/. Published April 2017. Accessed January 26, 2021. 141. Argoff CE, Silvershein DI. A Comparison of Long- and Short-Acting Opioids for the Treatment of Chronic Noncancer Pain: Tailoring Therapy to Meet Patient Needs. Mayo Clin Proc. 2009;84(7):602-612. 142. U.S. Food and Drug Administration. New safety measures announced for extended-release and long- acting opioids. http://www.fda.gov/Drugs/DrugSafety/ InformationbyDrugClass/ucm363722.htm. Accessed 3-1- 18. Published September 20, 2015. Accessed. 143. Covington EC, Argoff CE, Ballantyne JC, et al. Ensuring Patient Protections When Tapering Opioids: Consensus Panel Recommendations. Mayo Clin Proc. 2020;95(10):2155-2171. 144. Centers for Disease Control and Prevention. Calculating Total Daily Dose of Opioids for Safer Dosage. https:// www.cdc.gov/drugoverdose/pdf/calculating_total_daily_ dose-a.pdf. Accessed 7-18-19. 145. Knotkova H, Fine PG, Portenoy RK. Opioid rotation: the science and the limitations of the equianalgesic dose table. J Pain Symptom Manage. 2009;38(3):426-439. 146. Fine PG, Portenoy RK. Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage. 2009;38(3):418-425. 147. Centers for Disease Control and Prevention. Preventing an opioid overdose. https://www.cdc.gov/drugoverdose/.../ Preventing-an-Opioid-Overdose-Tip-Card-a.pdf. Accessed 3-20-18. 148. Passik SD, Kirsh KL, Whitcomb L, et al. Monitoring outcomes during long-term opioid therapy for noncancer pain: results with the Pain Assessment and Documentation Tool. J Opioid Manag. 2005;1(5):257-266. 149. Kroenke K, Spitzer RL, Williams JB, Löwe B. The Patient Health Questionnaire Somatic, Anxiety, and Depressive Symptom Scales: a systematic review. Gen Hosp Psychiatry. 2010;32(4):345-359. 150. Saunders JB. Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Curr Opin Psychiatry. 2017;30(4):227-237. 151. Centers for Disease Control and Prevention. Pocket Guide: Tapering Opioids for Chronic Pain. https://www.cdc.gov/ drugoverdose/prescribing/clinical-tools.html. Accessed December 17, 2019. 152. Prescribing Information: SUBOXONE (buprenorphine and naloxone). https://www.suboxone.com/pdfs/prescribing- information.pdf. Accessed December 17, 2019. 153. Lin LA, Ilgen MA, Jannausch M, Bohnert KM. Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. Addict Behav. 2016;61:99-103.
154. Morasco B, Nugent, S. Management of Chronic Pain with Medical Marijuana: Clinical Correlates and an Update on the Evidence: Oregon Health & Science University. https://pdfs.semanticscholar.org/presentatio n/57df/1d81edbe674117 6552a06300e0db8512d60a. pdf. Accessed 4-10-18. 155. Savage SR, Romero-Sandoval A, Schatman M, et al. Cannabis in Pain Treatment: Clinical and Research Considerations. J Pain. 2016;17(6):654-668. 156. Adamson SJ, Kay-Lambkin FJ, Baker AL, et al. An improved brief measure of cannabis misuse: the Cannabis Use Disorders Identification Test-Revised (CUDIT-R). Drug Alcohol Depend. 2010;110(1-2):137-143. 157. Lee CM, Neighbors C, Hendershot CS, Grossbard JR. Development and preliminary validation of a comprehensive marijuana motives questionnaire. J Stud Alcohol Drugs. 2009;70(2):279-287. 158. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13-20.
27
Powered by FlippingBook